Engitix: Funding, Investors & Team (Sep 2026)
Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. Engitix’ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.
Engitix has raised $79.0M across 2 funding rounds on record, the most recent a Series A of $25.0M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Engitix Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Engitix Funding Rounds
Engitix raised $54.0M in a Series A announced in Jan 2022.
4 years later, a Series A of $25.0M was announced in Jan 2026.
Engitix Founders and Leadership Team
Contact details for the Engitix team: 1 of 1 has an email address on file.
Start 14-day free trial →Engitix Funding Compared to Other Biotechnology Startups
Engitix's latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Engitix in Biotechnology and London
Companies Similar to Engitix
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Engitix Funding FAQs
What does Engitix do?
Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. Engitix’ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.
How much funding has Engitix raised?
Engitix has raised $79.0M across 2 rounds on record. The most recent is a Series A of $25.0M announced in Jan 2026.
When did Engitix last raise funding?
Engitix's most recent funding round on record is a Series A of $25.0M, announced in Jan 2026.
Who is the CEO of Engitix?
Giuseppe Mazza is listed as CEO at Engitix.
Where is Engitix headquartered?
Engitix is based in London, England, United Kingdom.
How many employees does Engitix have?
Engitix is in the 11-50 employee band.
How does Engitix's funding compare to other Biotechnology startups?
Engitix's latest round of $25.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Engitix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Engitix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.